PMC:7253235 / 42101-43184 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1371","span":{"begin":111,"end":115},"obj":"Gene"},{"id":"1372","span":{"begin":117,"end":121},"obj":"Gene"},{"id":"1373","span":{"begin":122,"end":125},"obj":"Gene"},{"id":"1379","span":{"begin":38,"end":46},"obj":"Species"},{"id":"1380","span":{"begin":230,"end":238},"obj":"Species"},{"id":"1381","span":{"begin":435,"end":443},"obj":"Species"},{"id":"1382","span":{"begin":797,"end":804},"obj":"Species"},{"id":"1383","span":{"begin":831,"end":839},"obj":"Species"},{"id":"1408","span":{"begin":31,"end":37},"obj":"Disease"},{"id":"1409","span":{"begin":81,"end":87},"obj":"Disease"},{"id":"1410","span":{"begin":250,"end":264},"obj":"Disease"},{"id":"1411","span":{"begin":316,"end":330},"obj":"Disease"},{"id":"1412","span":{"begin":552,"end":566},"obj":"Disease"},{"id":"1413","span":{"begin":745,"end":757},"obj":"Disease"},{"id":"1414","span":{"begin":948,"end":951},"obj":"Disease"},{"id":"1415","span":{"begin":984,"end":990},"obj":"Disease"}],"attributes":[{"id":"A1371","pred":"tao:has_database_id","subj":"1371","obj":"Gene:2064"},{"id":"A1372","pred":"tao:has_database_id","subj":"1372","obj":"Gene:673"},{"id":"A1373","pred":"tao:has_database_id","subj":"1373","obj":"Gene:5609"},{"id":"A1379","pred":"tao:has_database_id","subj":"1379","obj":"Tax:9606"},{"id":"A1380","pred":"tao:has_database_id","subj":"1380","obj":"Tax:9606"},{"id":"A1381","pred":"tao:has_database_id","subj":"1381","obj":"Tax:9606"},{"id":"A1382","pred":"tao:has_database_id","subj":"1382","obj":"Tax:9606"},{"id":"A1383","pred":"tao:has_database_id","subj":"1383","obj":"Tax:9606"},{"id":"A1408","pred":"tao:has_database_id","subj":"1408","obj":"MESH:D009369"},{"id":"A1409","pred":"tao:has_database_id","subj":"1409","obj":"MESH:D009369"},{"id":"A1410","pred":"tao:has_database_id","subj":"1410","obj":"MESH:D066126"},{"id":"A1411","pred":"tao:has_database_id","subj":"1411","obj":"MESH:D066126"},{"id":"A1412","pred":"tao:has_database_id","subj":"1412","obj":"MESH:D066126"},{"id":"A1413","pred":"tao:has_database_id","subj":"1413","obj":"MESH:D050171"},{"id":"A1415","pred":"tao:has_database_id","subj":"1415","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)\n• Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T118","span":{"begin":859,"end":863},"obj":"Body_part"},{"id":"T119","span":{"begin":867,"end":871},"obj":"Body_part"},{"id":"T120","span":{"begin":909,"end":914},"obj":"Body_part"},{"id":"T121","span":{"begin":924,"end":929},"obj":"Body_part"}],"attributes":[{"id":"A118","pred":"fma_id","subj":"T118","obj":"http://purl.org/sig/ont/fma/fma24728"},{"id":"A119","pred":"fma_id","subj":"T119","obj":"http://purl.org/sig/ont/fma/fma24728"},{"id":"A120","pred":"fma_id","subj":"T120","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A121","pred":"fma_id","subj":"T121","obj":"http://purl.org/sig/ont/fma/fma67264"}],"text":"Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)\n• Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T55","span":{"begin":859,"end":863},"obj":"Body_part"},{"id":"T56","span":{"begin":867,"end":871},"obj":"Body_part"},{"id":"T57","span":{"begin":909,"end":914},"obj":"Body_part"}],"attributes":[{"id":"A55","pred":"uberon_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"A56","pred":"uberon_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"A57","pred":"uberon_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)\n• Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T422","span":{"begin":31,"end":37},"obj":"Disease"},{"id":"T423","span":{"begin":81,"end":87},"obj":"Disease"},{"id":"T424","span":{"begin":745,"end":757},"obj":"Disease"},{"id":"T425","span":{"begin":948,"end":951},"obj":"Disease"},{"id":"T426","span":{"begin":984,"end":990},"obj":"Disease"}],"attributes":[{"id":"A422","pred":"mondo_id","subj":"T422","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A423","pred":"mondo_id","subj":"T423","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A424","pred":"mondo_id","subj":"T424","obj":"http://purl.obolibrary.org/obo/MONDO_0002525"},{"id":"A425","pred":"mondo_id","subj":"T425","obj":"http://purl.obolibrary.org/obo/MONDO_0005009"},{"id":"A426","pred":"mondo_id","subj":"T426","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)\n• Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T310","span":{"begin":605,"end":612},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T311","span":{"begin":859,"end":863},"obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"T312","span":{"begin":867,"end":871},"obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"T313","span":{"begin":909,"end":914},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T314","span":{"begin":909,"end":914},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"}],"text":"Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)\n• Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T117","span":{"begin":122,"end":125},"obj":"Chemical"},{"id":"T118","span":{"begin":338,"end":352},"obj":"Chemical"},{"id":"T120","span":{"begin":924,"end":929},"obj":"Chemical"}],"attributes":[{"id":"A117","pred":"chebi_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/CHEBI_28398"},{"id":"A118","pred":"chebi_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/CHEBI_48120"},{"id":"A119","pred":"chebi_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/CHEBI_49322"},{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_18059"}],"text":"Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)\n• Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T235","span":{"begin":31,"end":37},"obj":"Phenotype"},{"id":"T236","span":{"begin":81,"end":87},"obj":"Phenotype"},{"id":"T237","span":{"begin":745,"end":757},"obj":"Phenotype"},{"id":"T238","span":{"begin":948,"end":951},"obj":"Phenotype"},{"id":"T239","span":{"begin":984,"end":990},"obj":"Phenotype"}],"attributes":[{"id":"A235","pred":"hp_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A236","pred":"hp_id","subj":"T236","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A237","pred":"hp_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/HP_0003119"},{"id":"A238","pred":"hp_id","subj":"T238","obj":"http://purl.obolibrary.org/obo/HP_0001635"},{"id":"A239","pred":"hp_id","subj":"T239","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)\n• Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}

{"project":"LitCovid-sentences","denotations":[{"id":"T267","span":{"begin":0,"end":227},"obj":"Sentence"},{"id":"T268","span":{"begin":228,"end":463},"obj":"Sentence"},{"id":"T269","span":{"begin":464,"end":625},"obj":"Sentence"},{"id":"T270","span":{"begin":626,"end":699},"obj":"Sentence"},{"id":"T271","span":{"begin":700,"end":804},"obj":"Sentence"},{"id":"T272","span":{"begin":805,"end":952},"obj":"Sentence"},{"id":"T273","span":{"begin":953,"end":1083},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)\n• Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic\n• Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable\n• Limited imaging protocols to evaluate LVEF to minimize acquisition time\n• Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient\n• Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)\n• Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms"}